TY - JOUR
T1 - Clinical features associated with COVID-19 outcome in multiple myeloma
T2 - First results from the International Myeloma Society data set
AU - Chari, Ajai
AU - Samur, Mehmet Kemal
AU - Martinez-Lopez, Joaquin
AU - Cook, Gordon
AU - Biran, Noa
AU - Yong, Kwee
AU - Hungria, Vania
AU - Engelhardt, Monika
AU - Gay, Francesca
AU - Feria, Ana García
AU - Oliva, Stefania
AU - Oostvogels, Rimke
AU - Gozzetti, Alessandro
AU - Rosenbaum, Cara
AU - Kumar, Shaji
AU - Stadtmauer, Edward A.
AU - Einsele, Hermann
AU - Beksac, Meral
AU - Weisel, Katja
AU - Anderson, Kenneth C.
AU - Mateos, María Victoria
AU - Moreau, Philippe
AU - San-Miguel, Jesus
AU - Munshi, Nikhil C.
AU - Avet-Loiseau, Hervé
N1 - Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/12/24
Y1 - 2020/12/24
N2 - The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
AB - The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
UR - http://www.scopus.com/inward/record.url?scp=85098492928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098492928&partnerID=8YFLogxK
U2 - 10.1182/blood.2020008150
DO - 10.1182/blood.2020008150
M3 - Article
C2 - 33156904
AN - SCOPUS:85098492928
SN - 0006-4971
VL - 136
SP - 3033
EP - 3040
JO - Blood
JF - Blood
IS - 26
ER -